https://www.selleckchem.com/pr....oducts/acalabrutinib
Triple-negative breast cancer (TNBC) is characterised by high pathological complete response to neoadjuvant chemotherapy (NAC). However, refractory and poor NAC responders still face very poor outcome, emphasising the urgent need for tools that facilitate identification of these patients, so that surgery or alternatives to NAC are considered early in the treatment protocol. We combined metabolomics, exosome circulating miRNAsand flow cytometry experimental approaches in TNBC patients at diagnosis with immunohistochemistry in needl
Like
Comment
Share
